Rockefeller Capital Management L.P. Sells 188,092 Shares of Simulations Plus, Inc. $SLP

Rockefeller Capital Management L.P. lessened its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 25.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 557,866 shares of the technology company’s stock after selling 188,092 shares during the quarter. Rockefeller Capital Management L.P. owned approximately 2.77% of Simulations Plus worth $10,170,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new position in Simulations Plus during the second quarter valued at $25,000. Quarry LP purchased a new stake in Simulations Plus in the 3rd quarter worth $28,000. Caitong International Asset Management Co. Ltd lifted its stake in Simulations Plus by 343.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock worth $73,000 after purchasing an additional 3,084 shares in the last quarter. CWM LLC boosted its holdings in shares of Simulations Plus by 160.2% during the 4th quarter. CWM LLC now owns 5,480 shares of the technology company’s stock valued at $100,000 after purchasing an additional 3,374 shares during the last quarter. Finally, US Bancorp DE boosted its holdings in shares of Simulations Plus by 32.5% during the 3rd quarter. US Bancorp DE now owns 6,167 shares of the technology company’s stock valued at $93,000 after purchasing an additional 1,513 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.

Analysts Set New Price Targets

SLP has been the subject of a number of research analyst reports. TD Cowen cut their price objective on Simulations Plus from $19.00 to $16.00 and set a “hold” rating for the company in a research report on Friday, April 10th. Weiss Ratings upgraded Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, June 5th. Craig Hallum lowered Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price target for the company. in a research note on Thursday, June 18th. Wall Street Zen cut Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Finally, William Blair downgraded Simulations Plus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 17th. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Simulations Plus presently has a consensus rating of “Hold” and an average price target of $20.90.

Simulations Plus Stock Up 0.1%

Simulations Plus stock opened at $18.16 on Thursday. The company’s 50-day moving average price is $15.64 and its 200-day moving average price is $15.55. The company has a market cap of $366.93 million, a PE ratio of -5.80 and a beta of 1.33. Simulations Plus, Inc. has a twelve month low of $11.09 and a twelve month high of $21.01.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Thursday, April 9th. The technology company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.08. The firm had revenue of $24.29 million during the quarter, compared to the consensus estimate of $21.66 million. Simulations Plus had a negative net margin of 77.96% and a positive return on equity of 16.21%. As a group, sell-side analysts expect that Simulations Plus, Inc. will post 0.8 earnings per share for the current fiscal year.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.